CEO says new acquisition unlikely soon....

Discussion in 'Takeda' started by anonymous, Sep 6, 2017 at 10:53 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    according to recent Wall Street Journal article. What about new business development for primary care?
     

  2. anonymous

    anonymous Guest

  3. anonymous

    anonymous Guest

    Come on, it's not like they're going to come out and say "we plan on shuttering the whole primary care franchise and just focus on the specialty groups" are they???

    If you are still in Takeda primary care, you are the ones left behind
     
  4. anonymous

    anonymous Guest

    Absolutely Not... that is what BJ said when asked if Takeda was getting out of PCP.....s
    o transparent
     
  5. anonymous

    anonymous Guest

    Was that before or after the business development guy?
     
  6. anonymous

    anonymous Guest

    Primary care is extinct in 2 years. After Dex loses patent and Obamacare collapses, it's hari kari time.
     
  7. anonymous

    anonymous Guest

    also he said restructuring is done next year. The artical said that for R&D, but the fact is they are not done restructuring. Should not be surprised if they continue with sales too...who knows. They are in a cost cutting phase at this point and usually not a good sign...
    There are so many Reps leaving, maybe they don't have to have another layoff hahaha
     
  8. anonymous

    anonymous Guest

    Of course they are not..Takeda management is going to ride the Primary Care Horse HARD till it's dead and that will be in about 2 years.
     
  9. anonymous

    anonymous Guest

    You can bet your sweet ass it will be sooner than 2 years. Upper management said we were sized right through 2019. CEO is feeling heat and takeda has nothing coming with no new deals. Money is getting tighter. Only time will tell, but March 2018 and our end of fiscal year, could be an interesting month.
     
  10. anonymous

    anonymous Guest

    This is my feeling too...
     
  11. anonymous

    anonymous Guest

    If history repeats itself ZS probably has already finalized the plan and Takeda Management is fully aware.
     
  12. anonymous

    anonymous Guest

    anyone think it could happen by the holidays ?
     
  13. anonymous

    anonymous Guest

    sure. Have to believe any end of quarter there is a chance for something to happen. Highest chance is EOY march 31 AKA takeda new year.
     
  14. anonymous

    anonymous Guest

    Was that before or after the Blow Job? LOL
     
  15. anonymous

    anonymous Guest

    During all three phases. Before, to get the BJ, during, because if felt so good, and after, because he couldn't think straight.

    Whether it's before the holidays or end of fiscal, multiple plans were probably made and signed off on this past summer. Given what CEO just said, plan B will now go into effect. Adding 20 specialty reps keeps people calm, creates security for 20 more people, gives the company more focus and direction for specialty, ZS will re draw the lines and decide who is cut and who stays and promoting those 20 reps will give ZS a better picture. They still need a certain percentage of PCP reps to meet detail commitments for Amitiza and Trintellix. Hospital systems continue to by and control PCP offices and have stopped seeing reps or don't take samples. ZS will continue to use that to figure needs in territories. We also help make their analysis easier through FPP by telling how many details we can get on doctors and who we can't see. Last layoff proved in many geographies that we are going to 2 reps in territories. Now in many geographies 2 reps will cover a larger area or will cover two territories. They were probably testing waters on 2 Rep theory last layoff. Uloric and Dexilant in many areas only have 1 Rep promoting and now we have mail order samples that you could select in FPP. If you selected that for your territory, then you screwed yourself. Promo for those products may go to nothing. Really what have they really been investing into those two products over the last few years. Their future, for now is squeezing everything out of Amitiza due to market noise and Trintellix because while we still see growth, they want and need faster growth.
     
  16. anonymous

    anonymous Guest

     
  17. anonymous

    anonymous Guest

    PP your spot on. Those 20 positions freed up with speciality advancement allocation says re-drawing of lines..Notice in QA that issue was addressed loosely..
     
  18. anonymous

    anonymous Guest

    Chat up the Sr Admins next time your in the home office. You would be surprised at how much they know about these things well in advance of these announcements.
     
  19. anonymous

    anonymous Guest


    Well since we're not in the home office or close by please continue to be our mole and grill those admins~